We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
-7.53%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$319M
AUM Growth
-$42M
Cap. Flow
-$13.7M
Cap. Flow %
-4.3%
Top 10 Hldgs %
40.4%
Holding
86
New
14
Increased
23
Reduced
18
Closed
23

Top Buys

1
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M
2
BHVN icon
Biohaven
BHVN
+$8.11M
3
CGON icon
CG Oncology
CGON
+$6.41M
4
KRRO icon
Korro Bio
KRRO
+$5.53M
5
SYRE icon
Spyre Therapeutics
SYRE
+$5.07M

Top Sells

1
SRPT icon
Sarepta Therapeutics
SRPT
+$8.99M
2
JBIO
Jade Biosciences
JBIO
+$6.65M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$5.92M
4
TGTX icon
TG Therapeutics
TGTX
+$5.19M
5
AXSM icon
Axsome Therapeutics
AXSM
+$4.44M

Sector Composition

1 Healthcare 89.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN icon
1
Biohaven
BHVN
$2.32B
$17M 5.33%
490,000
+205,000
+72% +$8.11M
ALNY icon
2
PUT
Alnylam Pharmaceuticals
ALNY
$35.7B
$16.6M 5.2%
+68,400
New +$10.8M
INSM icon
3
CALL
Insmed
INSM
$23.5B
$13.4M 4.2%
+200,000
New +$7.76M
MLTX icon
4
MoonLake Immunotherapeutics
MLTX
$1.64B
$13.2M 4.13%
300,000
– –
SLNO
5
DELISTED
Soleno Therapeutics
SLNO
$12.2M 3.83%
300,000
+100,000
+50% +$4.24M
AXSM icon
6
Axsome Therapeutics
AXSM
$11.8B
$12.1M 3.78%
150,000
-60,000
-29% -$4.44M
ASND icon
7
Ascendis Pharma A/S
ASND
$17.1B
$11.8M 3.7%
+86,721
New +$11.8M
PCVX icon
8
Vaxcyte
PCVX
$8.12B
$11.3M 3.55%
150,000
+55,000
+58% +$3.74M
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$8.88B
$10.7M 3.37%
240,000
+40,000
+20% +$1.85M
ROIV icon
10
Roivant Sciences
ROIV
$24.8B
$10.6M 3.31%
1,000,000
-300,000
-23% -$3.29M
CATX icon
11
Perspective Therapeutics
CATX
$341M
$9.22M 2.89%
925,000
+325,000
+54% +$4.7M
TGTX icon
12
TG Therapeutics
TGTX
$8.4B
$8.89M 2.79%
500,000
-325,000
-39% -$5.19M
SRPT icon
13
Sarepta Therapeutics
SRPT
$1.82B
$8.69M 2.72%
55,000
-70,000
-56% -$8.99M
CGON icon
14
CG Oncology
CGON
$6.34B
$8.21M 2.57%
260,000
+185,000
+247% +$6.41M
CRBP icon
15
Corbus Pharmaceuticals
CRBP
$167M
$7.92M 2.48%
175,000
+118,059
+207% +$4.97M
VRDN icon
16
Viridian Therapeutics
VRDN
$1.99B
$7.65M 2.39%
587,708
-37,292
-6% -$516K
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$2.02B
$7.19M 2.25%
350,000
+200,000
+133% +$4.19M
IMVT icon
18
Immunovant
IMVT
$8.27B
$6.86M 2.15%
260,000
+135,000
+108% +$3.84M
TARS icon
19
Tarsus Pharmaceuticals
TARS
$2.61B
$6.39M 2%
235,000
-65,000
-22% -$2.19M
PHAT icon
20
Phathom Pharmaceuticals
PHAT
$873M
$6.18M 1.94%
600,000
+115,000
+24% +$1.18M
RZLT icon
21
Rezolute
RZLT
$444M
$6.11M 1.91%
+1,421,501
New +$4.88M
OLMA icon
22
Olema Pharmaceuticals
OLMA
$1B
$5.95M 1.86%
550,000
+350,000
+175% +$3.8M
SYRE icon
23
Spyre Therapeutics
SYRE
$8.7B
$5.88M 1.84%
250,237
+150,237
+150% +$5.07M
ALNY icon
24
Alnylam Pharmaceuticals
ALNY
$35.7B
$5.47M 1.71%
22,500
-37,500
-63% -$5.92M
APLS
25
DELISTED
Apellis Pharmaceuticals
APLS
$5.18M 1.62%
135,000
+5,000
+4% +$226K
1
2 3 4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Ghost Tree Capital held 86 positions worth $319M, down 12% from $361M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Ghost Tree Capital withdrew a net $13.7M in Q2 2024, closing 23 positions and reducing 18 holdings. Its most notable exit was Jade Biosciences, an estimated $6.65M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 85% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Ascendis Pharma A/S worth $11.8M.

  • Ghost Tree Capital's largest Q2 2024 buy was Ascendis Pharma A/S: 86,721 shares worth $11.8M.
  • Ghost Tree Capital added most to Biohaven in Q2 2024, an estimated $8.11M increase.
  • Ghost Tree Capital's biggest Q2 2024 reduction was Sarepta Therapeutics, cutting an estimated $8.99M.
  • Ghost Tree Capital fully exited Jade Biosciences in Q2 2024, selling an estimated $6.65M.
  • Ghost Tree Capital's ten largest holdings make up 40% of its $319M portfolio in Q2 2024.
  • Ghost Tree Capital opened 14 new positions and closed 23 in Q2 2024.
  • Ghost Tree Capital's portfolio value fell 12% quarter-over-quarter to $319M.

Based on Ghost Tree Capital's 13F filing for Q2 2024, filed 14 Aug 2024.